Floatz logo

Romidepsin

Enteropathy-Associated T-Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Enteropathy-Associated T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Eric Jacobsen, MD
Phase 4BBB
Inno-206
Eric Jacobsen, MD
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
Ifosfamide
Shandong Provincial Hospital
Phase 4BB
PREDNISONE TABLETS
Eric Jacobsen, MD
Phase 4BB

View all 36 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →